DRKS00004345已完成不适用
Symptom Experience of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Following High Dose Chemotherapy - syMMex
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •All Patients with MM, and 18 years of age and older admitted to one of the three transplant wards of the Department of Hematology/Oncology, University Medical Center, Freiburg, Germany, for HD and ASCT will be screened for inclusion criteria and consecutively included in the study. The criteria for inclusion are that the patients are able to read, understand, and answer the PROVIVO questionnaire and that HD and ASCT is part of the first treatment regimen after diagnosis.
排除标准
- 未提供
研究者
相似试验
尚未招募
不适用
Clinical Symptoms of Multiple Myeloma and their Validity in the Detection of symptomatic Progression and RelapseC90.0Multiple myelomaDRKS00024789niversitätsklinikum Freiburg500
尚未招募
不适用
Clinical Profile Of Multiple MyelomaCTRI/2021/08/035576Kasturba Medical College
已完成
不适用
Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General HospitalBlood - Haematological diseasesMultiple MyelomaACTRN12612000024842Clifford Craig Medical Trust Fund10
进行中（未招募）
不适用
Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III studyMultiple MyelomaEUCTR2005-003770-23-ATF. Hoffmann-La Roche Ltd424
已完成
不适用
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)Multiple MyelomaNCT03188536Takeda282